Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosmidomycin-Piperaquine in Acute Uncomplicated Plasmodium Falciparum Malaria
NCT02198807Phase 2Unknown
- Sponsor
- DMG Deutsche Malaria
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of fosmidomycin in Plasmodium falciparum malaria, sponsored by DMG Deutsche Malaria. Primary endpoint: PCR-corrected cure rate at Day 28. Status: unknown.
02
Drugs
fosmidomycin
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT02198807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02198807.